Johnson & Johnson approaches Actelion about takeover deal


U.S. healthcare company Johnson & Johnson said on Friday it was in preliminary talks with Actelion about a potential takeover of Europe's largest biotech firm, currently valued at about $20 billion. A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel February 17, 2015.



from Biotech News